LON:AGL

ANGLE Interim Earnings Report

ANGLE logo
GBX 2.35 -0.30 (-11.32%)
As of 10/28/2025

ANGLE EPS Results

Actual EPS
-GBX 2.87
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ANGLE Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ANGLE Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

ANGLE Earnings Headlines

Angle PLC
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does. But the real opportunity isn't the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI's Colossus infrastructure buildout - and a specific trigger in the S-1 could reprice it overnight.tc pixel
Discovering UK Penny Stocks: ANGLE And 2 Other Top Picks
See More ANGLE Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ANGLE? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ANGLE and other key companies, straight to your email.

About ANGLE

ANGLE (LON:AGL), a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

View ANGLE Profile